Surrozen, Inc. (NASDAQ:SRZN), a biopharmaceutical company, has reported the resignation of Tim Kutzkey, Ph.D., from its board of directors, effective as of Monday. According to the company's latest SEC filing, Dr. Kutzkey's departure from the board and all its committees does not stem from any disagreement over the company's operations, policies, or practices.
The biotech firm, headquartered in South San Francisco, California, specializes in biological products and is known by its former name, Consonance-HFW Acquisition Corp., which it changed from on September 15, 2020. The company's common stock and redeemable warrants are traded on The Nasdaq Capital Market under the symbols SRZN and SRZNW, respectively.
Surrozen has not yet announced a successor or provided details on the process for filling the vacancy left by Dr. Kutzkey. His resignation comes as Surrozen continues to navigate the biotech industry, focusing on developing treatments using its proprietary platform.
The company's filing with the SEC, dated July 1, 2024, serves as the official source of this announcement. It's important to note that Surrozen is classified as an emerging growth company and as such, is subject to specific reporting and regulatory standards.
Investors and stakeholders will be watching closely to see how this change will impact Surrozen's strategic direction and governance. The company has yet to comment on the future direction of the board or on any potential candidates to fill the now-vacant position.
This news is based on a press release statement and reflects the latest information made available by Surrozen, Inc. through its SEC filing.
In other recent news, Surrozen, Inc. has been making significant strides in both its research and clinical trials. The biotechnology firm has reported promising preclinical data for its antibody-based Wnt mimetic technologies, suggesting potential new treatments for corneal endothelial damage and Dry Eye Disease.
In addition, the company has successfully completed a Phase 1a clinical trial for its drug candidate SZN-043, showing it to be safe and well-tolerated, and is advancing into a Phase 1b proof-of-concept trial for severe alcohol-associated hepatitis.
Surrozen has also secured a private placement agreement that will provide an initial $17.5 million in funding, with the potential for up to $175 million more upon warrant exercises. This funding will extend the company's financial runway and expand the Phase 1b clinical trial for its severe alcohol-associated hepatitis treatment. These are recent developments that highlight the company's ongoing research and development efforts.
The company's research indicates that its Wnt mimetic can stimulate endothelial cell proliferation in the cornea, potentially halting vision loss in conditions such as Fuchs’ Endothelial Cell Dystrophy. Surrozen's Wnt signal activating proteins (SWAP) technology is designed to mimic natural Wnt proteins, crucial for tissue repair and regeneration.
The company's SWAP antibodies selectively activate Wnt signaling, which has been demonstrated to induce cell proliferation and tissue regeneration in preclinical studies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.